A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the safety of combining selinexor with
daunorubicin and cytarabine. The maximal tolerated dose (MTD) of selinexor with daunorubicin
and cytarabine will also be established.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute